Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous ThromboembolismEIKELBOOM, John W; ZELENKOFSKE, Steven L; RUSCONI, Christopher P et al.Arteriosclerosis, thrombosis, and vascular biology. 2010, Vol 30, Num 3, pp 382-387, issn 1079-5642, 6 p.Article

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarctionANAVEKAR, Nagesh S; MCMURRAY, John J. V; ZELENKOFSKE, Steven et al.The New England journal of medicine. 2004, Vol 351, Num 13, pp 1285-1295, issn 0028-4793, 11 p.Article

A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensivesWEIR, Matthew R; FERDINAND, Keith C; FLACK, John M et al.Hypertension (Dallas, Tex. 1979). 2005, Vol 46, Num 3, pp 508-513, issn 0194-911X, 6 p.Article

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary InterventionCOHEN, Mauricio G; PURDY, Drew A; ZELENKOFSKE, Steven et al.Circulation (New York, N.Y.). 2010, Vol 122, Num 6, pp 614-622, issn 0009-7322, 9 p.Article

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitusHOLLENBERG, Norman K; PARVING, Hans-Henrik; VIBERTI, Giancarlo et al.Journal of hypertension. 2007, Vol 25, Num 9, pp 1921-1926, issn 0263-6352, 6 p.Article

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothPFEFFER, Marc A; MCMURRAY, John J. V; LEIMBERGER, Jeffrey D et al.The New England journal of medicine. 2003, Vol 349, Num 20, pp 1893-1906, issn 0028-4793, 14 p.Article

Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both : the VALIANT Echo StudyMERIS, Alessandra; AMIGONI, Maria; GHALI, Jalal et al.European heart journal. 2009, Vol 30, Num 1, pp 56-65, issn 0195-668X, 10 p.Article

Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. CommentaryDENARDO, Scott J; ANDERSON, R. David; ROULEAU, Jean L et al.Hypertension (Dallas, Tex. 1979). 2008, Vol 51, Num 1, issn 0194-911X, 26-27, 48-54 [9 p.]Article

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trialPOVSIC, Thomas J; COHEN, Mauricio G; RUSCONI, Christopher P et al.The American heart journal. 2011, Vol 161, Num 2, pp 261-268, issn 0002-8703, 8 p.Article

Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudyPOVSIC, Thomas J; WARGIN, William A; RUSCONI, Christopher P et al.European heart journal. 2011, Vol 32, Num 19, pp 2412-2419, issn 0195-668X, 8 p.Article

Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or BothPOULEUR, Anne-Catherine; BARKOUDAH, Ebrahim; MAGGIONI, Aldo P et al.Circulation (New York, N.Y.). 2010, Vol 122, Num 6, pp 597-602, issn 0009-7322, 6 p.Article